Influenza medical therapy

Influenza Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Influenza from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
Other Diagnostic Studies
Treatment
Medical Therapy
Primary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Influenza medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Influenza medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Influenza medical therapy
CDC on Influenza medical therapy
Influenza medical therapy in the news
Blogs on Influenza medical therapy
Directions to Hospitals Treating Influenza
Risk calculators and risk factors for Influenza medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohammad Braizat, M.S. [2]

Influenza Medical Therapy

Medical therapy for influenza centers on prompt antiviral treatment — ideally within 48 hours of symptom onset — in patients who are hospitalized, have severe or progressive illness, or are at higher risk of complications, combined with supportive care. Four FDA-approved agents are currently recommended in the US: oral oseltamivir, inhaled zanamivir, intravenous peramivir, and oral baloxavir marboxil. Adamantanes (amantadine, rimantadine) are no longer recommended due to near-universal resistance. Adjunctive corticosteroids are not recommended in influenza and are associated with harm in observational data.

Indications for Antiviral Treatment

CDC and AAP recommend antiviral treatment as early as possible for any patient with confirmed or suspected influenza who:

• Is hospitalized
• Has severe, complicated, or progressive illness
• Is at higher risk for influenza-associated complications

Treatment should be started empirically without waiting for confirmatory testing. While benefit is greatest within 48 hours, treatment initiated later still provides benefit in hospitalized patients, those with severe disease, and those with progressive illness.

Higher-risk groups (CDC/AAP):

• Children <5 years (especially <2 years)
• Adults ≥65 years
• Pregnancy and up to 2 weeks postpartum
• Chronic pulmonary (including asthma), cardiovascular (excluding isolated hypertension), renal, hepatic, neurologic, and hematologic disorders
• Immunocompromise (including HIV, malignancy, transplant recipients, chronic steroids)
• Obesity (BMI ≥40 kg/m²)
• Residents of long-term care facilities
• American Indian/Alaska Native persons
• Persons <19 years receiving long-term aspirin or salicylate therapy

In low-risk outpatients with uncomplicated influenza, any of the four agents may be used; treatment is optional and driven by symptom burden and timing.

Agent Selection and Dosing

Agent	Route / Mechanism	Adult Treatment Dose	Pediatric Treatment Dose	Key Considerations	References
Oseltamivir	Oral NAI, 5 days	75 mg BID × 5 d	≤15 kg: 30 mg BID; >15–23 kg: 45 mg BID; >23–40 kg: 60 mg BID; >40 kg: 75 mg BID; 2 weeks to <1 year: 3 mg/kg/dose BID	Preferred agent for hospitalized, severe, or high-risk patients and in pregnancy; enterically administrable via NG/OG tube; renal dose adjustment required; nausea/vomiting most common AE; neuropsychiatric events reported (rare)
Baloxavir	Oral cap-dependent endonuclease inhibitor, single dose	20–<80 kg: 40 mg × 1; ≥80 kg: 80 mg × 1	≥5 years (otherwise healthy); ≥12 years (high-risk): 15–<20 kg: 30 mg × 1; 20–<80 kg: 40 mg × 1; ≥80 kg: 80 mg × 1	Superior viral load reduction and influenza B efficacy vs oseltamivir; better GI tolerability; not recommended in pregnancy, breastfeeding, severe immunosuppression, hospitalized patients, or progressive illness; avoid co-administration with dairy, calcium, iron, magnesium, zinc, antacids; CENTERSTONE trial suggests reduced household transmission
Zanamivir	Inhaled NAI, 5 days	10 mg (two 5-mg inhalations) BID × 5 d	≥7 years: same as adult	Not recommended in chronic airway disease (asthma, COPD) due to bronchospasm risk; dry powder — never nebulize or give via ventilator circuit; insufficient data in hospitalized patients
Peramivir	IV NAI, single dose	600 mg IV over 15–30 min	6 mo–12 yr: 12 mg/kg (max 600 mg); ≥13 yr: 600 mg	FDA-approved from age 6 months; CDC Yellow Book recommends for patients ≥2 years; useful when oral/enteral route unavailable; efficacy in hospitalized patients not established; renal dose adjustment required

Duration of therapy:

• Uncomplicated influenza: 5 days for oseltamivir/zanamivir; single dose for baloxavir/peramivir
• Hospitalized/severe influenza: 5 days (may extend up to 10 days in immunocompromised or severely ill patients with persistent symptoms)

Renal dose adjustment (oseltamivir, adults, treatment):

• CrCl >60–90 mL/min: 75 mg BID
• CrCl >30–60 mL/min: 30 mg BID
• CrCl >10–30 mL/min: 30 mg once daily
• Hemodialysis: 30 mg after each dialysis session (max 5 days)
• CAPD: single 30 mg dose after a dialysis exchange

Peramivir renal adjustment: CrCl 30–49 mL/min → 200 mg; CrCl 10–29 mL/min → 100 mg; hemodialysis → dose after dialysis.

Preterm/neonatal oseltamivir dosing (by postmenstrual age): <38 weeks — 1.0 mg/kg/dose BID; 38–40 weeks — 1.5 mg/kg/dose BID; >40 weeks — 3.0 mg/kg/dose BID. Consult pediatric ID for extremely preterm infants.

Efficacy Evidence

Outpatient Influenza (Non-Severe)

A 2025 JAMA Internal Medicine network meta-analysis of 73 RCTs (34,332 patients) provided the following high-quality estimates:

• Baloxavir may reduce hospital admission in high-risk patients (RD −1.6%, 95% CI −2.0 to 0.4; low certainty), probably reduces time to symptom alleviation (MD −1.02 days; moderate certainty), and had fewer treatment-related adverse events (RD −3.2%; high certainty)
• Oseltamivir had little or no effect on hospital admission in high-risk patients (RD −0.4%; high certainty), probably no important effect on symptom duration (MD −0.75 days; moderate certainty), and probably increased adverse events (RD +2.8%; moderate certainty)
• All antivirals had little or no effect on mortality in low- and high-risk patients (high certainty)

The CENTERSTONE trial demonstrated that baloxavir reduces household transmission of influenza, providing an additional rationale for its use in index cases where transmission prevention is a priority.

Hospitalized Influenza (Severe)

No adequately powered RCT exists. A 2024 Lancet network meta-analysis found only low-certainty evidence that oseltamivir and peramivir might reduce duration of hospitalization, with great uncertainty regarding mortality. Observational data are more favorable:

• Target trial emulation of 11,073 hospitalized adults (Ontario, 2015–2023): oseltamivir within 2 days of admission was associated with an adjusted in-hospital mortality risk difference of −1.8% (95% CI −2.8% to −0.9%), earlier discharge (aSHR 1.20), and lower 30-day readmission
• US sentinel surveillance of 840 hospitalized adults: oseltamivir started on admission day was associated with lower peak pulmonary severity (aOR 0.60), ICU admission (aOR 0.24), and in-hospital death (aOR 0.36)

Guideline Positions

The 2024 WHO guideline (summarized as a BMJ Rapid Recommendation) conditionally recommends oseltamivir for severe illness and baloxavir for patients at high risk of progression from non-severe to severe illness, both within 48 hours of onset. The 2023 ERS/ESICM/ESCMID/ALAT severe CAP guideline recommends oseltamivir for influenza-associated severe CAP based on observational data alone (individual-patient meta-analysis of 5,103 ICU patients: OR 0.72, 95% CI 0.56–0.94 for mortality). AAP considers oseltamivir the drug of choice in children and the only agent it recommends for hospitalized children.

Special Populations

• Pregnancy and lactation: Oseltamivir is preferred; extensive safety data exist. ACOG and CDC recommend oseltamivir for pregnant and postpartum patients with suspected or confirmed influenza. Baloxavir is not recommended in pregnancy or breastfeeding due to absent data.
• Neonates and preterm infants: FDA-approved from 2 weeks of age; CDC and AAP support use from birth in term and preterm infants, as benefit likely outweighs risk.
• Severe immunosuppression: Baloxavir is not recommended as monotherapy due to risk of rapid emergence of PA-I38X resistance mutations under prolonged viral replication. ECIL-10 recommends treating hematologic malignancy and HCT patients for 5–10 days or until clinically significant improvement, extending to at least 10 days if influenza testing remains positive at 5–7 days (grade BIII); patients failing to improve after 5 days of NAI therapy should be re-evaluated for coinfection (grade BIII).
• Chronic airway disease: Inhaled zanamivir is not recommended due to bronchospasm risk.
• Reye syndrome: Aspirin and salicylate-containing products should be avoided in patients <19 years with influenza or varicella.

Management of Severe/Hospitalized Influenza

Oseltamivir is the preferred agent for hospitalized patients. The standard duration is 5 days, but longer courses (up to 10 days) may be considered in immunocompromised patients with prolonged shedding or severe disease. A multicenter cohort of critically ill patients suggested progressively lower ICU mortality with durations beyond 9–10 days; this is unvalidated in RCTs.

No benefit to double-dose neuraminidase inhibitor therapy has been demonstrated; a meta-analysis of 10 studies (20,947 patients) showed no reduction in mortality or improvement in viral clearance versus standard dosing. An RCT of baloxavir plus NAI combination therapy in hospitalized patients ≥12 years showed no superiority over NAI alone.

Corticosteroids should NOT be used in influenza unless there is a separate indication (e.g., refractory shock, underlying autoimmune disease). A Cochrane meta-analysis of 21 observational studies (9,536 patients) reported markedly higher mortality with corticosteroids (OR 3.90, 95% CI 2.31–6.60), although adjusted subgroup analyses attenuated the association (aOR 1.31, 95% CI 0.95–1.80) — consistent with confounding by indication. Corticosteroids also increase hospital-acquired infection risk and may prolong viral shedding.

Supportive care includes antipyretics/analgesics, hydration, and oxygen as needed. Antibacterial therapy should be reserved for documented or strongly suspected bacterial coinfection.

Antiviral Resistance

Global WHO GISRS surveillance (2020–2023) found resistance remains rare overall. Clinically actionable resistance points:

• NA-H275Y in A(H1N1)pdm09 confers cross-resistance to oseltamivir and peramivir but not zanamivir
• PA-I38T/M/L substitutions confer reduced baloxavir susceptibility; treatment-emergent resistance peaks in children 2–4 years of age and is more common with A(H3N2)
• Resistance can emerge during therapy, particularly in severely immunocompromised patients with prolonged shedding
• >99% of circulating influenza A viruses remain adamantane-resistant

Antiviral Shortages

When antiviral supply is constrained, AAP recommends prioritizing treatment for:

• Hospitalized patients
• Patients with severe or progressive illness
• Patients at highest risk for complications (children <2 years, immunocompromised, chronic medical conditions)

Chemoprophylaxis

For post-exposure prophylaxis, antiviral chemoprophylaxis is an adjunct to vaccination, not a substitute. Indications and dosing:

• Post-exposure prophylaxis (oseltamivir or zanamivir): 10 days duration; recommended for high-risk patients and unvaccinated household contacts. Only for children ≥3 months (oseltamivir) or ≥5 years (zanamivir).
• Community outbreak (long-term care facilities): Up to 6 weeks duration
• Immunocompromised patients: Up to 12 weeks duration

Areas of Uncertainty and Guideline Disagreement

1. Baloxavir vs. oseltamivir first-line. WHO conditionally recommends baloxavir for high-risk non-severe influenza, whereas CDC and AAP continue to name oseltamivir the preferred agent, with baloxavir positioned as an alternative when adherence or tolerance is a concern. AAP notes CDC does not recommend baloxavir in hospitalized, severely immunosuppressed, pregnant, or breastfeeding patients. 2. No RCT establishes mortality benefit of any antiviral in severe influenza. The 2024 Lancet network meta-analysis rated the evidence as low to very low certainty; guideline recommendations rest on extrapolation and observational data. 3. Optimal treatment duration in critically ill patients remains uncertain; standard is 5 days but some observational data suggest longer courses may be beneficial. 4. Peramivir age indication discrepancy: FDA approves from 6 months; CDC Yellow Book recommends for patients ≥2 years. 5. Whether baloxavir's resistance liability offsets its efficacy advantages remains unresolved, particularly in young children and A(H3N2) seasons.

Common Clinical Considerations

• Do not delay treatment for test results in hospitalized or high-risk patients — empiric therapy at presentation is associated with the largest benefit.
• Oseltamivir on hospital admission day (not later) is the exposure associated with reduced ICU admission and mortality in observational studies.
• Baloxavir has superior efficacy against influenza B than oseltamivir; consider it in confirmed influenza B in eligible outpatients.
• Oseltamivir is the only agent with robust pregnancy safety data and is the drug of choice in pregnant and postpartum patients. ACOG specifically recommends oseltamivir in this population.
• Oseltamivir can be given via NG/OG tube — a practical advantage in intubated ICU patients over inhaled zanamivir.
• Baloxavir must be separated from polyvalent cations (dairy, calcium, iron, magnesium, zinc, antacids), which impair absorption.
• Neuropsychiatric events have been reported with oseltamivir (rare), particularly in children and adolescents; FDA labeling includes this warning.
• Extending oseltamivir beyond 5 days is reasonable in severely immunocompromised patients with persistently positive testing at day 5–7.

Common Pitfalls

1. Withholding antivirals because >48 hours have elapsed in a hospitalized or deteriorating patient — later treatment still provides benefit in moderate-to-severe or progressive disease. 2. Prescribing inhaled zanamivir to asthma or COPD patients — not recommended due to bronchospasm risk. 3. Using baloxavir in pregnancy, severe immunosuppression, or hospitalized patients — outside CDC-endorsed use and unsupported by data. 4. Failing to renally dose oseltamivir or peramivir, particularly in elderly patients with reduced CrCl. 5. Adding corticosteroids for "influenza ARDS" without an independent indication — associated with increased mortality signal and hospital-acquired infection. 6. Reflexive antibiotics for non-severe influenza — WHO issues a strong recommendation against this. 7. Assuming a negative rapid antigen test excludes influenza in a high-risk patient — treat empirically when clinical suspicion is high. 8. Using baloxavir in children <5 years (or <12 years with high-risk conditions) — outside the labeled indication.